Recent News
Powered by Alpha Vantage
No recent news found.
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs for the treatment of cancer and other proliferative diseases. The company is headquartered in Berkeley Heights, New Jersey.
52W High
$283.40
52W Low
$3.08
MA Status:
50D: Below
200D: Below
Beta (~1 neutral, <0.9 lower risk)
0.16
Valuation
Attractive
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
0.00
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
0.02
EV/Revenue (<3 favorable)
1167.96
P/S (TTM) (<3 favorable)
1594.15
P/B (<3 favorable)
4.39
Ownership
Retail‑heavySource: Overview
Insiders (1–5% typical)
60.16%
Institutions (25–75% balanced)
0.80%
Shares Outstanding
2,239,000
Float
96,660
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
10,000
Gross Profit (TTM)
10,000
EPS (TTM)
7123.50
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
-1035.80%
ROE (TTM) (>15% strong)
-2.77%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
-1.00
Momentum
Value
N/A
Previous
N/A
Trend
—
Signal Cross
No cross
As of
—